Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melanie Thompson

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Plos One|September 8, 2011
Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San FranciscoAlbert Y Liu, Eric Vittinghoff, Deborah E Sellmeyer, et al.
Plos One|October 7, 2016
DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent VirusMelanie Thompson, Sonya L Heath, Bentley Sweeton, et al.
Plos One|June 28, 2016
Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney FibrosisEric Lefebvre, Graeme Moyle, Ran Reshef, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 11, 2017
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 ResultsJosé R Arribas, Melanie Thompson, Paul E Sax, et al.
The New England Journal of Medicine|March 27, 2020
Fostemsavir in Adults with Multidrug-Resistant HIV-1 InfectionMichael Kozal, Judith Aberg, Gilles Pialoux, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 6, 2007
Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatmentAlan Landay, Barbara A da Silva, Martin S King, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 8, 2013
Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United StatesLisa A Grohskopf, Kata L Chillag, Roman Gvetadze, et al.
The Journal of Infectious Diseases|January 31, 2007
Whole-blood interleukin-18 level during early HIV-1 infection is associated with reduced CXCR4 coreceptor expression and interferon- gamma levelsCarrie A Sailer, Gregory B Pott, Charles A Dinarello, et al.
Science (New York, N.Y.)|October 1, 2005
AIDS. Promote HIV chemoprophylaxis research, don't prevent itRobert M Grant, Susan Buchbinder, Willard Cates, et al.
Antiviral Therapy|October 2, 2003
A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adultsJacob P Lalezari, Edwin DeJesus, Donald W Northfelt, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Plos One|September 8, 2011
Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San FranciscoAlbert Y Liu, Eric Vittinghoff, Deborah E Sellmeyer, et al.
Plos One|October 7, 2016
DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent VirusMelanie Thompson, Sonya L Heath, Bentley Sweeton, et al.
Plos One|June 28, 2016
Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney FibrosisEric Lefebvre, Graeme Moyle, Ran Reshef, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 11, 2017
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 ResultsJosé R Arribas, Melanie Thompson, Paul E Sax, et al.
The New England Journal of Medicine|March 27, 2020
Fostemsavir in Adults with Multidrug-Resistant HIV-1 InfectionMichael Kozal, Judith Aberg, Gilles Pialoux, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 6, 2007
Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatmentAlan Landay, Barbara A da Silva, Martin S King, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 8, 2013
Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United StatesLisa A Grohskopf, Kata L Chillag, Roman Gvetadze, et al.
The Journal of Infectious Diseases|January 31, 2007
Whole-blood interleukin-18 level during early HIV-1 infection is associated with reduced CXCR4 coreceptor expression and interferon- gamma levelsCarrie A Sailer, Gregory B Pott, Charles A Dinarello, et al.
Science (New York, N.Y.)|October 1, 2005
AIDS. Promote HIV chemoprophylaxis research, don't prevent itRobert M Grant, Susan Buchbinder, Willard Cates, et al.
Antiviral Therapy|October 2, 2003
A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adultsJacob P Lalezari, Edwin DeJesus, Donald W Northfelt, et al.
Pageof 6